DrugBank 5.0: a major update to the DrugBank database for 2018

DrugBank 5.0: a major update to the DrugBank database for 2018

Published online 8 November 2017 | David S. Wishart1,2,3,4,*; Yannick D. Feunang1; An C. Guo1; Elvis J. Lo1; Ana Marcu1; Jason R. Grant1; Tanvir Sajed2; Daniel Johnson1; Carin Li1; Zinat Sayeeda1; Nazanin Assempour1; Ithayavani Lynkkaran1,4; Yifeng Liu2; Adam Maciejewski1; Nicola Gale5; Alex Wilson5; Lucy Chin5; Ryan Cummings5; Diana Le5; Allison Pon1,5; Craig Knox1,5 and Michael Wilson1,5
DrugBank 5.0 is a significant update to the DrugBank database, representing the most substantial expansion in over a decade. This update includes a 100% or more growth in existing data content, such as the number of investigational drugs, drug-drug interactions, and SNP-associated drug effects. New data fields have been added, including information on the influence of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics), and protein expression levels (pharmacoproteomics). Additionally, new data on clinical and pre-clinical drug trials, drug images, and predicted drug metabolites and spectra have been incorporated. The interface has been enhanced with mobile device compatibility, improved spectral viewing and searching tools, and new search features for pharmaco-omic queries. A new public-private partnership with OMx Personal Health Analytics Inc. ensures the sustainability and continued relevance of DrugBank for researchers, healthcare professionals, and the general public.DrugBank 5.0 is a significant update to the DrugBank database, representing the most substantial expansion in over a decade. This update includes a 100% or more growth in existing data content, such as the number of investigational drugs, drug-drug interactions, and SNP-associated drug effects. New data fields have been added, including information on the influence of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics), and protein expression levels (pharmacoproteomics). Additionally, new data on clinical and pre-clinical drug trials, drug images, and predicted drug metabolites and spectra have been incorporated. The interface has been enhanced with mobile device compatibility, improved spectral viewing and searching tools, and new search features for pharmaco-omic queries. A new public-private partnership with OMx Personal Health Analytics Inc. ensures the sustainability and continued relevance of DrugBank for researchers, healthcare professionals, and the general public.
Reach us at info@study.space